Compounded (@Compoundedhq) header
Compounded (@Compoundedhq) profile picture

An anonymous brief on how cash-pay healthcare gets built. Stack maps · regulatory analysis · corpus quarterlies. Bi-weekly. Faceless.

Joined May 2026
This is issue #1 of Compounded. An anonymous brief on how cash-pay healthcare actually gets built. Every claim sourced. Every operator gets right of reply.Full piece, 16 citations, the scenario math: compounded.health
3
So the trade isn't "the vote fails." It's that July 23 changes far less, far slower than the people betting on it think. Could we be wrong? ~25-30%. But even a yes doesn't make one peptide legal in 2026. To lose this you need the FDA to move fast. It never has.
1
3
And the evidence is thin. BPC-157: ~150 papers, 90% from one lab in Croatia, zero completed Western trials. A University of Utah physician on it: "We've cured cancer in mice plenty of times. Haven't done it in people yet." That's the FDA's briefing memo, basically.
1
1
The part nobody's pricing in: This same committee voted YES on glutathione in April 2022. Four years later, the rule still isn't final. Still not legal to compound. A "yes" on July 23 is a recommendation, not a law. The law takes years. Sometimes never.
1
1
Everyone's treating July 23 as one decision. It's three: RFK Jr. wants peptides freed (done) A scientific committee votes on the evidence The FDA writes the actual rule Only step 1 happened. Steps 2 and 3 are where the hype dies.
1
2
The FDA committee reviewing 7 peptides on July 23 (BPC-157, TB-500, Epitalon + more) has recommended ZERO of its first twelve substance reviews for approval. Twelve to nothing. The longevity industry is pricing in a 70% yes. 🧵
1
7